Dr. Reddy's Laboratories Ltd.

442 articles about Dr. Reddy's Laboratories Ltd.

• Dr. Reddy’s and GRA announces Avigan Pivotal Studies Update

  1/27/2021

  Study for hospitalized moderate to severe cases in Kuwait terminated, while study for out-patient mild to moderate cases continues in North America

• Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India

  1/11/2021

  Dr. Reddy’s Laboratories Ltd. announced that the independent Data and Safety Monitoring Board has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications.

• Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market

  1/11/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric Tablets approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS™ (favipiravir) Tablets for the Treatment of COVID-19 under Health Canada’s Interim Order

  12/22/2020

  Dr. Reddy’s Laboratories Ltd., Appili Therapeutics and Global Response Aid FZCO announced that Dr. Reddy’s Canada has filed an application on behalf of the consortium for REEQONUS™ Tablets for the acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.

• Secondary Listing of Dr. Reddy’s ADRs on NSE IFSC Limited (GIFT City, Gujarat, India)

  12/9/2020

  Dr. Reddy’s Laboratories Ltd. announced the secondary listing of its American Depository Receipts on NSE IFSC Limited under the symbol ’DRREDDY’ on December 9, 2020.

• Dr. Reddy’s to Acquire Select Anti-Allergy Brands from Glenmark in Russia, Ukraine, Kazakhstan and Uzbekistan 

  11/28/2020

  Dr. Reddy’s Laboratories Ltd. announced that it has entered into a definitive agreement with Glenmark Pharmaceuticals Ltd. to acquire, subject to completion of certain precedent actions and closing activities, brands Momat Rino, Momat Rino Advance, Momat A, Glenspray and Glenspray Active, along-with rights to the trademarks, dossiers and patents for the territories mentioned.

• Dr. Reddy’s Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tumor Growth Inhibition and Overall Survival Through a Combination of E7777 (Denileukin Diftitox) and an Immune Checkpoint Inhibitor

  11/9/2020

  Dr. Reddy’s Laboratories Ltd. announced a preclinical data presentation for E7777, its engineered IL-2-diphtheria toxin fusion protein, at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting, being held virtually.

• Dr. Reddy's partners with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India

  10/29/2020

  Dr. Reddy’s Laboratories Ltd., announced its partnership with Biotechnology Industry Research Assistance Council, Department of Biotechnology, Government of India, for advisory support on clinical trials of Sputnik V vaccine in India.

• Dr. Reddy’s Q2 & H1 FY21 Financial Results

  10/28/2020

  Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter and the half year ended September 30, 2020.

• Dr. Reddy's Laboratories Announces Appointment of New Chief Financial Officer

  10/28/2020

  Dr. Reddy’s Laboratories Ltd. announced that Parag Agarwal will be joining the Company as Chief Financial Officer on November 2, 2020.

• Dr. Reddy’s announces the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, store-brand equivalent of Pepcid AC® in the U.S. Market

  10/20/2020

  Dr. Reddy’s Laboratories Ltd. announced the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, the store-brand equivalents of Original Strength and Maximum Strength Pepcid AC®, in the U.S. market, as approved by the U.S. Food and Drug Administration.

• Dr. Reddy’s and RDIF receive approval to conduct clinical trial for Sputnik V vaccine in India

  10/17/2020

  Dr. Reddy’s Laboratories Ltd. and Russian Direct Investment Fund, Russia’s sovereign wealth fund, announced that they have received approval from the Drug Control General of India to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India.

• Dr. Reddy’s Laboratories Joins Science Based Targets initiative (SBTi) and Sets 2030 GHG Emission Targets

  10/5/2020

  Dr. Reddy’s Laboratories Ltd. has joined the Science Based Targets initiative’s business ambition for 1.5°C, becoming the first Indian and the third Asian pharmaceutical company to have set its Science-Based Targets to further minimize environmental impact.

• Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. Market

  10/3/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of a generic version of Sapropterin Dihydrochloride Tablets, for Oral Use.

• Dr. Reddy's Laboratories Announces the Launch of Cinacalcet Tablets in the U.S. Market

  10/1/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar Tablets, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Dimethyl Fumarate Delayed-Release Capsules in the U.S. Market

  9/26/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera® Delayed-Release Capsules, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's announces the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market

  9/25/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex® in 0.9% Sodium Chloride Injection, approved by the U.S. Food and Drug Administration.

• Dr. Reddy’s announces the launch of Over-the-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalent of Pataday®, the Eye Allergy Drop in the U.S. Market

  9/17/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of over-the-counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalents of Pataday® Once Daily Relief and Pataday® Twice Daily Relief, in the U.S. market, as approved by the U.S. Food and Drug Administration.

• RDIF and Dr. Reddy's to cooperate on clinical trials and supply of 100 million doses of Sputnik V vaccine to India

  9/16/2020

  The Russian Direct Investment Fund, Russia's sovereign wealth fund, and Dr. Reddy's Laboratories Ltd., a global pharmaceutical company headquartered out of India, have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India.

• Dr. Reddy's Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market

  9/9/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of over-the-counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. market.